Montelukast
- Generic Name
- Montelukast
- Brand Names
- Singulair
- Drug Type
- Small Molecule
- Chemical Formula
- C35H36ClNO3S
- CAS Number
- 158966-92-8
- Unique Ingredient Identifier
- MHM278SD3E
- Background
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...
- Indication
Montelukast is indicated for:
...
- Associated Conditions
- Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- JHSPH Center for Clinical Trials
- Target Recruit Count
- 500
- Registration Number
- NCT00156819
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸University of Miami (and University of South Florida in Tampa), Miami, Florida, United States
Trial of Asthma Patient Education (TAPE)
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2010-04-30
- Target Recruit Count
- 600
- Registration Number
- NCT00148408
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Miami (and University of South Florida in Tampa), Miami, Florida, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
Montelukast in the Treatment of Duodenal Eosinophilia
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-12-29
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 24
- Registration Number
- NCT00148603
- Locations
- 🇺🇸
Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 102
- Registration Number
- NCT00119015
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Predicting the Response to Montelukast by Genetic Variation in Asthmatics
- Conditions
- First Posted Date
- 2005-06-29
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT00116324
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Montelukast for Early Life Wheezing
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 62
- Registration Number
- NCT00115297
- Locations
- 🇺🇸
University of Massachusetts/UMass Memorial, Worcester, Massachusetts, United States
The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1992
- Registration Number
- NCT00092118
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.